Ablacon, Inc. - acquired by Boston Scientific

Ablacon, Inc. is a medical technology company based in Wheat Ridge, Colorado, founded in 2015. The company specializes in AI-enabled electrotherapy solutions for treating Atrial Fibrillation (AFib) and other arrhythmic heart disorders. Ablacon developed an advanced mapping system that utilizes artificial intelligence algorithms and computer vision to visualize Electrographic Flow, allowing for precise localization and characterization of AFib sources.

The core offering of Ablacon is its AI-based mapping system, which analyzes electrographic data to identify AFib drivers and guide targeted catheter ablation therapy. This technology enhances treatment precision for AFib, the most common cardiac arrhythmia. Ablacon operated internationally, with teams in Switzerland, Germany, and the U.S., and received a CE Mark in 2018, facilitating access to the European market. The company was acquired by Boston Scientific, further expanding its reach in the medical technology field.